Position in GLUE
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$18,029,000
New position
Shares Held
745,000
first reported quarter
Ownership
0.873%
of shares outstanding
% of Portfolio
1.65%
of 13F equity value
Holder Rank
#29
of 193 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026Opaleye Management Inc. holds $678,840,611 across 50 Biotechnology names. GLUE ranks #14 (2.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | IRON |
Disc Medicine, Inc.
|
855,000 | $62,534,700 | |
| 2 | URGN |
UroGen Pharma Ltd.
|
1,439,996 | $52,991,852 | |
| 3 | APGE |
Apogee Therapeutics, Inc.
|
390,000 | $51,764,700 | |
| 4 | MGTX |
MeiraGTx Holdings plc
|
3,550,000 | $47,960,500 | |
| 5 | SLGL |
Sol-Gel Technologies Ltd.
|
500,000 | $37,070,000 | |
| 6 | RZLT |
Rezolute, Inc.
|
6,300,000 | $32,760,000 | |
| 7 | TGTX |
Tg Therapeutics, Inc.
|
535,000 | $29,392,900 | |
| 8 | IMMX |
Immix Biopharma, Inc.
|
2,345,000 | $24,176,950 |
All Filings in GLUE
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $18,029,000 | 745,000 | Shares | Sole | 2026-08-14 | |
| No filing history on record for this holder in this stock. | ||||||